TrialInternational journal of hematology2025

A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia.

Masashi Sawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.